Chapuy CI, et al. - In this work, researchers focused on daratumumab, a human IgG1κ monoclonal antibody targeting CD38, used to treat multiple myeloma. They delineated a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation successfully treated with daratumumab.

• From an HLA-matched, unrelated donor with a major ABO incompatibility (blood group A in the donor and blood group O in the recipient), a 72-year-old man with the myelodysplastic syndrome received a transplant.
• Clinicians identified persistent circulating anti-A antibodies and no red-cell recovery 200 days after transplantation in this patient.
• No effect from standard treatments was evident.
• Transfusions were no longer required for the patient within 1 week after the initiation of treatment with daratumumab.